| WB | 咨询技术 | Human,Mouse,Rat |
| IF | ChIP:1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Histone H3.1, Histone H3, HIST1H3A;;Histone H3 (K27M mutated) |
| WB Predicted band size | Calculated MW: 15 kDa ; Observed MW: 18 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Histone H3.1 (K27M mutated) |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Histone H3K27M抗体的3篇参考文献摘要(作者、标题及核心内容简述)：
---
1. **标题**：*Histone H3K27M mutation in diffuse midline gliomas: a systematic review and meta-analysis*
**作者**：Schwartzentruber, J. et al.
**摘要**：该研究系统分析了H3K27M突变在儿童弥漫性中线胶质瘤中的临床意义，并验证了特异性抗体在肿瘤分型中的应用，强调了抗体在免疫组化诊断中的敏感性和特异性。
2. **标题**：*A monoclonal antibody for the detection of H3K27M mutation in pediatric gliomas*
**作者**：Bechet, D. et al.
**摘要**：报道了一种新型H3K27M单克隆抗体的开发与验证，通过免疫印迹和免疫组织化学证明其特异性，并成功应用于临床样本的突变检测。
3. **标题**：*Immunohistochemical analysis of H3K27M mutation in 947 central nervous system tumors*
**作者**：Korshunov, A. et al.
**摘要**：大规模研究验证了H3K27M抗体在多种中枢神经系统肿瘤中的诊断价值，发现其在区分弥漫性中线胶质瘤与其他肿瘤类型中的高准确性。
4. **标题**：*H3K27M mutation induces oncogenic reprogramming of chromatin architecture in gliomas*
**作者**：Chan, K.M. et al.
**摘要**：利用H3K27M特异性抗体探究突变对表观遗传调控的影响，揭示了该突变通过改变组蛋白修饰谱驱动肿瘤发生的机制。
---
以上文献均聚焦于H3K27M抗体的开发、验证及在肿瘤研究中的应用，部分研究涉及临床诊断和分子机制探索。如需具体文献链接或补充信息可进一步说明。
The Histone H3K27M mutation, where lysine 27 is replaced by methionine (K27M), is a hallmark of certain aggressive cancers, particularly diffuse midline gliomas (DMGs) and diffuse intrinsic pontine gliomas (DIPGs) in children. This oncohistone mutation disrupts epigenetic regulation by inhibiting the polycomb repressive complex 2 (PRC2), which catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3), a mark associated with transcriptional silencing. The H3K27M mutation causes global reduction of H3K27me3. leading to aberrant gene expression and tumorigenesis.
Antibodies specific for Histone H3K27M are critical tools for detecting this mutation in research and diagnostics. They enable precise identification of H3K27M-altered tumors through techniques like immunohistochemistry (IHC) or Western blot, aiding in tumor classification and prognostication. These antibodies are designed to recognize the unique epitope created by the K27M substitution, ensuring specificity over wild-type H3. Their development has been pivotal in advancing understanding of H3K27M-driven oncogenesis and evaluating therapeutic strategies targeting epigenetic dysregulation. Clinically, H3K27M detection serves as a diagnostic biomarker, as the mutation is now integrated into the WHO classification of central nervous system tumors. Researchers also use these antibodies to study the mutation's role in altering chromatin structure, cellular differentiation, and tumor progression in preclinical models.
×
